

1 **Disrupted topological properties of structural brain networks present a**
2 **glutamatergic neuropathophysiology in people with narcolepsy**

3 Guoyan Chen^{1†}, Wen Wang^{2†}, Haoyang Wu^{3†}, Xiangchao Zhao^{1†}, Xiaopeng Kang⁴, Jiafeng
4 Ren¹, Jun Zhang¹, Jiaxiu He¹, Shihui Sun¹, Zhao Zhong¹, Danqing Shang¹, Mengmeng Fan¹,
5 Jinxiang Cheng¹, Dan Zhang¹, Changjun Su^{1*} and Jiaji Lin^{1,5*}

6 1 Department of Neurology, The Second Affiliated Hospital of Air Force Medical University,
7 No.569 Xinsi Road, Xi'an, 710038, China

8 2 Department of Radiology, The Second Affiliated Hospital of Air Force Medical University,
9 No.569 Xinsi Road, Xi'an, 710038, China

10 3 Basic Medicine School, Air Force Medical University, No.169 Changle West Road, Xi'an,
11 710038, China

12 4 School of Artificial Intelligence, University of Chinese Academy of Sciences, No.19A
13 Yuquan Road, Beijing, 100876, China.

14 5 Department of Radiology, Chinese PLA General Hospital/Medical School of Chinese PLA,
15 No.28 Fuxing Road, Beijing, 100853, China

16 †These authors contributed equally to this work.

17 *Correspondence to:

18 Jiaji Lin, Department of Neurology, The Second Affiliated Hospital of Air Force Medical
19 University, No.569 Xinsi Road, Xi'an, 710038, China. Tel: 86-29-84777743 E-mail:
20 jjajj90@outlook.com & Changjun Su, Department of Neurology, The Second Affiliated
21 Hospital of Air Force Medical University, No.569 Xinsi Road, Xi'an, 710038, China. Tel: 86-
22 29-84777744 E-mail: tdneurob@fmmu.edu.cn

23

Abstract (250 words)

24 **Study objectives:** Growing evidences have documented various abnormalities of the white
25 matter bundles in people with narcolepsy. We sought to evaluate topological properties of
26 brain structural networks, and their association with symptoms and neuropathophysiological
27 features in people with narcolepsy.

28 **Methods:** Diffusion tensor imaging (DTI) was conducted for people with narcolepsy (n = 30)
29 and matched healthy controls as well as symptoms assessment. Structural connectivity for
30 each participant was generated to analyze global and regional topological properties and their
31 correlations with narcoleptic features. Further human brain transcriptome was extracted and
32 spatially registered for connectivity vulnerability. Genetic functional enrichment analysis was
33 performed and further clarified using *in vivo* emission computed tomography data.

34 **Results:** A wide and dramatic decrease in structural connectivities was observed in people
35 with narcolepsy, with descending network degree and global efficiency. These metrics were
36 not only correlated with sleep latency and awakening features, but also reflected alterations of
37 sleep macrostructure in people with narcolepsy. Network-based statistics identified a small
38 hyperenhanced subnetwork of cingulate gyrus that was closely related to rapid eye movement
39 sleep behavior disorder (RBD) in narcolepsy. Further imaging genetics analysis suggested
40 glutamatergic signatures were responsible for the preferential vulnerability of connectivity
41 alterations in people with narcolepsy, while additional PET/SPECT data verified that
42 structural alteration was significantly correlated with metabotropic glutamate receptor 5
43 (mGluR5) and N-methyl-D-aspartate receptor (NMDA).

44 **Conclusions:** People with narcolepsy endured a remarkable decrease in the structural
45 architecture, which was not only be closely related to narcolepsy symptoms but also
46 glutamatergic signatures.

47 **Keywords:** narcolepsy; structural network; topological property; glutamatergic receptor;

48 cingulate gyrus

49

50

Statement of Significance (120 words)

51 Growing evidences have identified a widespread disrupted white matter integrity of people
52 with narcolepsy, so that connectome properties and neuropathophysiological features
53 underlying these abnormalities have become a topic of increasing interest. This report
54 extends on findings regarding the structural wirings and architectural topology of people with
55 narcolepsy and inferring their clinical correlation with sleepiness assessment,
56 polysomnography features and sleep macrostructure. Further imaging genetics analysis
57 suggests glutamatergic signatures are responsible for the preferential vulnerability of
58 connectivity alterations, while additional PET/SPECT data verifies that structural alteration is
59 significantly correlated with metabotropic glutamate receptor 5 (mGluR5) and N-methyl-D-
60 aspartate receptor (NMDA). Our findings, therefore, converge structural network and genetic
61 signatures for in people with narcolepsy.

62

63

Main text

64 1. Introduction

65 Narcolepsy is conceptualized as a state of instability or loss of boundary control that
66 manifests as an inability to remain in sleep or wake states for the normal length of time and
67 by the inappropriate occurrence of sleep phenomena during wakefulness, and vice versa ¹. Its
68 onset peaks in the second decade of life and affects 1 in 2,000 people, and most people with
69 narcolepsy also have symptoms indicative of cataplexy, sleep paralysis, hypnagogic
70 hallucinations and disturbed nocturnal sleep ¹. A variety of neuroplastic alterations have been
71 found to be closely associated with this wakefulness/sleep disturbances. Positron emission
72 tomography (PET) study of Trotti et al. showed hypermetabolism in precuneus, inferior
73 parietal lobule, superior and middle temporal gyri, and culmen ². In another study that used
74 functional magnetic resonance imaging (fMRI), functional connectivity was decreased
75 between regions of the limbic system and the default mode network (DMN) and increased in
76 the visual network ³. Furthermore, N-acetylaspartate/creatine-phosphocreatine in
77 hypothalamus and myo-Inositol/ creatine-phosphocreatine in the amygdalain was reported to
78 link with narcolepsy in 1H-MRS study of Joo et al ⁴. Although disrupted functional activities
79 have been widely reported in narcolepsy, the potential clinical implications of structural
80 connectome abnormalities have not been systematically investigated.

81 The key attribute of the structural connectome is the large investment of neural
82 resources in macroscale connectivity to keep the brain globally connected, with a
83 considerable proportion of the anatomical communication pathways comprising white matter
84 ⁵. Cross-species studies on these wirings have revealed common “principles of network”
85 appear to be widely conserved and represent fundamental features of brain organization and
86 function ⁶. Considerable effort in the past decade has been directed towards identifying

87 network substrates and biomarkers that predict disease severity, prognosis and outcome of
88 specific brain disorders, such as deglobalization in the DMN and motor network in Alzheimer
89 disease and ALS ^{7,8}, fluctuation in functional network dynamics in epilepsy ⁹,
90 hyperconnectivity in autism spectrum disorder ¹⁰, and so on. In recent years, growing
91 evidences from diffusion tensor imaging (DTI) have documented a number of abnormalities
92 of the white matter bundles in people with narcolepsy. For example, Gool et al. have found
93 brain-wide significantly lower fractional anisotropy (FA) in sleep-wake regulation-related,
94 limbic and reward system areas of drug-free people with narcolepsy type 1, which was
95 sensitive to the fibers alignment and the myelination integrity ¹¹. Similar FA decreases have
96 also been confirmed in the bilateral cerebellar hemispheres, bilateral thalami, corpus
97 callosum and midbrain white matter of people with narcolepsy type 2 ^{12,13}. Therefore, further
98 analysis with network neuroscience tools may help us to discover topological features
99 specific to this disease.

100 Therefore, current study obtained MR imaging from people with narcolepsy for
101 structural connectome analysis. By characterizing alteration of global and regional signatures,
102 we further associated them to clinical symptoms as well as underlying
103 neuropathophysiological susceptibilities, which was further clarified by *in vivo* emission
104 computed tomography data.

105 **2. Materials and methods**

106 **2.1 Experiment design and participants**

107 This was a prospective observational neuroimaging study aimed at exploring the clinical
108 and brain imaging features of people with narcolepsy (NCT03376568), which was registered
109 in 2016. It was approved by the Ethics Committee of the Second Affiliated Hospital (also

110 named as Tangdu Hospital) of Air Force Medical University, and all participants and their
111 families were fully informed and signed an informed consent form for the operation. From
112 December 2017 to December 2022, over 100 participants complaining about daily periods of
113 irrepressible need to sleep or daytime lapses into sleep occurring for at least three months
114 were recruited at our narcolepsy clinic and signed up for the study. All subjects had to be 18-
115 65 years old, treatment-naïve, right-handed according to the Edinburgh Handedness Scale ¹⁴
116 and have normal or corrected-to-normal vision. To be included, people should be diagnosed
117 as narcolepsy type 1/2 (with/without cataplexy) according to the 3rd edition of the
118 International Classification of Sleep Disorders (ICSD-3) ¹⁵. Briefly, they took sleep diaries
119 and actigraphy for two weeks for exclusion of sleep deprivation, insufficient sleep syndrome
120 and circadian rhythm sleep-wake disorders. Any medication or intervention should be
121 avoided during this period, and sleep breathing disorder, depression or other potential sleep
122 disorders were also excluded. At the end, polysomnography (PSG) and MSLT were
123 performed according to standard techniques as AASM recommendation ¹⁶. A mean sleep
124 latency of ≤ 8 minutes and two or more sleep onset REM periods (SOREMPs) on multiple
125 sleep latency test (MSLT) performed according to standard techniques. A SOREMP (within
126 15 minutes of sleep onset) on the preceding nocturnal PSG may replace one of the SOREMPs
127 in the MSLT. All recruited participants received MRI acquisition and symptom assessment
128 on the next day.

129 The exclusion criteria included severe systematic diseases, central neurodegenerative
130 diseases, cognitive impairment, unstable psychiatric diseases, structural brain abnormalities,
131 history of intracranial hemorrhage or strokes, history of bleeding or coagulation
132 abnormalities, inability to tolerate prolonged stationary position when supine, history of brain
133 surgery, and contraindications for MRI scanning. Beck depression/anxiety inventory was

134 used to initially screen out psychiatric disorder (cutoff $\leq 4/13$ respectively), while Mini-
135 Mental Status Exam (MMSE) was the tool used to screen out obvious cognitive dysfunction
136 (cutoff = 27, adjusted by education level as need). The data of 30 participants with narcolepsy
137 were finally included for present study, and additional 30 healthy controls (HCs) with
138 matched gender, age and education level were also enrolled by the same exclusion criteria at
139 the same time and received the same MRI scanning as people with narcolepsy. All raw data
140 are available on request within the conditions of our ethics approval.

141 **2.2 Narcoleptic symptom assessment**

142 In addition to general characteristics (age, gender and previous medication use),
143 participants and their first-degree relatives underwent clinical consultations and semi-
144 structured interviews about narcoleptic symptoms (excessive daytime sleepiness (EDS), rapid
145 eye movement (REM) sleep behavior disorder (RBD), cataplexy, sleep paralysis, and
146 hypnagogic hallucination). The Epworth Sleepiness Scale (ESS) (Johns, 1991) was
147 administered as a measure of EDS. ESS score > 10 is defined as EDS. The diagnose of RBD
148 is were characterized by any complaining of probable RBD (repeated sleep related
149 vocalization and/or complex motor behaviors) and REM sleep without atonia (RWA) with
150 the guidance of AASM manual v2.4¹⁶.

151 We also ascertained a wide range of PSG parameters, including total sleep time (TST),
152 sleep efficiency with respect to both total registration and total sleep time, percentage of sleep
153 stages N1, N2, N3, and REM (with respect to total sleep time), sleep latency to the first
154 occurrence of any sleep stage from light off, wake time after sleep onset (WASO), awakening
155 number per hour (AWN) and apnea-hypopnea index (AHI). Technicians awakened the
156 participants after a registration time of roughly 7.5 hours.

157 **2.3 MR imaging data acquisition**

158 All MR images were acquired using a 3.0T MR imaging system (Discovery 750; GE
159 Healthcare, Milwaukee, WI, USA) equipped with a 64-channel phase array coil. Both
160 Diffusion tensor imaging (DTI) and High-resolution sagittal 3D T1-weighted imaging (3D
161 T1WI) were operated under quality control and assurance guidelines in accordance with the
162 recommendations of the American College of Radiology and utilized the same imaging
163 sequence. Participants were instructed to lie supine, relax, remain still, keep awake with eyes
164 closed, and think of nothing during MRI acquisition. They wore ear plugs to reduce noise. To
165 minimize head motion, tight but comfortable foam padding was placed around their heads.
166 The MRI scanning protocol included the following: (1) DTI: repetition time/echo time (TR /
167 TE) = 7,522/80.8 ms; field of view (FOV) = 224 × 224; matrix = 112 × 112; b value = 1,000
168 sec/mm²; encoding directions = 64; slice thickness = 2 mm; and B₀ = 4. (2) 3D T1WI:
169 TR/TE = 6.656 / 2.928 ms; inversion time = 800 ms; FA = 7°; FOV = 256 mm × 256 mm;
170 matrix = 256 × 256; slice thickness = 1 mm; contiguous slices = 190. Two senior radiologists
171 independently reviewed the aforementioned sequences, and carefully checked the quality of
172 MRI images.

173 **2.4 Network construction and subnetwork extract**

174 DTI data were preprocessed using the DiffusionKit toolbox as previous report ¹⁷.
175 Briefly, the process included: (1) converting to DICOM data; (2) extracting a brain mask; (3)
176 correcting for head motion and eddy current; (4) fitting diffusion tensors and performing
177 tractography with a deterministic streamline method with the fractional anisotropy (FA)
178 threshold of 0.3 and the angular threshold of 45°; (5) registering regions of interest (ROIs)
179 from Montreal Neurological Institute (MNI) space to the individual space; (6) pruning tract
180 for each ROI pair in the Brainnetome atlas (atlas.brainnetome.org) ¹⁸. Brainnetome atlas

181 includes middle frontal gyrus (MFG), parahippocampal gyrus (PhG), cingulate gyrus (CG),
182 basal ganglia (BG) and other contralateral 24 partitions. The streamline number was referred
183 to as connectivity by calculating for the tracts linking each pair of brain regions. All
184 connectivity pairs were collected and then combined into 246×246 undirected and
185 weighted connectivity matrix as global structural network. All ROI full names and
186 abbreviations of the Brainnetome atlas could be found in Supplementary Table 1.

187 Considering the regional variation in the structural subnetwork, network-based statistic
188 was used to identify expansive disconnected subnetworks¹⁹. This non-parametric
189 connectome-wide method is based on the principles underpinning traditional cluster-based
190 thresholding of statistical parametric maps, and exploits the extent to which the connections
191 comprising the contrast or effect of interest are interconnected¹⁹. Network-based statistics
192 were performed with 5,000 permutations for weighted structural network comparisons
193 between the participants and matched HCs. A threshold of $t \geq 3$ were applied for
194 streamline comparison with a significance of $P < 0.05$ for permutation test.

195 **2.5 Graph-Theory network analysis**

196 We applied a sparsity threshold of 10% for the weighted network of each participant to
197 avoid false connections. All graph-theory network analyses in this study were performed
198 using the Brant toolbox (<https://github.com/yongliulab/brant/>)²⁰. Topological metrics were
199 calculated for each participant, reflecting different aspects of the structural network
200 properties, including: (1) network/nodal degree is the most commonly used as a measure of
201 the wiring strength and coherence of anatomical network/ROI. The degree of an individual
202 node not only reflects the cumulative “wiring cost” distribution of the regional network, but
203 is also used as a measure of density distribution²¹. (2) global/nodal efficiency is measure of
204 integration, which assessed parallel information transfer within a structural network/ROI. (3)

205 clustering coefficient is measure of segregation, which is known as the fraction of triangles
206 around an individual node, and the mean clustering coefficient for the network reflects, on
207 average, the prevalence of clustered connectivity. Detailed calculation formulas of these
208 metrics are the same as described in the works of Sporns et al ²¹⁻²⁵ .

209 **2.6 Spatial alignment to neuropathophysiological features**

210 We investigated the underlying neuropathophysiological features of people with
211 narcolepsy using the human brain gene transcriptome data extracted from the Allen Human
212 Brain Atlas (AHBA) ²⁶. This atlas is the first anatomically and genomically comprehensive
213 three-dimensional human brain map, which contains a database of 20,737 gene expression
214 levels represented by 58,692 probes. We matched the gene expression for each ROI to the
215 Brainnetome atlas using the Abagen toolbox ^{27,28}, by setting the threshold for intensity-based
216 filtering of probes to 0.5. In the end, 236 ROI of 15,633 genes were extracted, resulting in a
217 $236 \times 15,633$ matrix for the alteration of nodal degree. Partial least squares (PLS) regression
218 algorithm, the statistically inspired modification of the partial least squares (SIMPLS), was
219 applied to investigate how genetic variance can explain brain structural alterations ²⁹. The
220 ranked gene list with principle PLS weights was fed into the online tool WebGestalt ³⁰ to
221 identify the functional enrichment by gene set enrichment analysis (GSEA) ³¹. The false
222 discovery rate (FDR) correction was applied, along with a significance of $P_{\text{FDR}} < \alpha 0.05$ for all
223 enrichment analyses. The entire workflow is shown in Supplementary Figure 1.

224 To further elucidate our GSEA results, we also introduced PET/SPECT maps of
225 glutamatergic neuropathophysiological features from unrelated control groups for spatial
226 alignment, which were collected by Justine et al ³². Specifically, the [¹¹C]ABP688 data for
227 the group I metabotropic glutamate receptor 5 (mGluR5) expression came from Rosa-Neto
228 team, Dubois team and Smart team respectively ³²⁻³⁴, while [¹⁸F]GE-179 data for the

229 ionotropic N-methyl-D-aspartate receptor (NMDA) expression came from Galovic's work³⁵.
230 The correlation was calculated between the effect sizes of the ROI t -values and regional sum
231 PET/SPECT values, resulting in a single measure for accessing the relationship between the
232 altered brain structure and the glutamatergic features. To avoid false-positive results of
233 spatial autocorrelation (SA), we generated 5,000 SA-preserving surrogate maps as null
234 models using brainSMASH as null models³⁶. The significance was calculated as $P_{Corr_SA} =$
235 $\frac{Count_{Greater}}{Count_{All}}$, where $Count_{Greater}$ was the number that surrogate's absolute correlation
236 coefficient was greater than that of the primary analysis. $Count_{All}$ were the times that
237 performed surrogate correlation, in this case, 5,000 times.

238 **2.7 Statistical Analysis and code availability**

239 Chi-square tests were used to detect group differences between people with narcolepsy
240 and matched HCs in the demographic analysis. Non-paired t -tests were used evaluate the
241 difference in each connectivity between people with narcolepsy and matched HCs, as well as
242 graph metrics comparisons between narcolepsy and HCs group in the graph-theory network
243 analysis. We further divided the people with narcolepsy into subgroups according to their
244 clinical symptoms (cataplexy, sleep paralysis, hypnagogic hallucination, and RBD), and
245 compared their graph metrics using non-paired t -tests too. Multiple comparison correlations
246 of FDR were applied in both network and regional topology features (marked with P_{FDR}).
247 When analyzing clinical relevance, Pearson and Spearman correlation coefficient served as a
248 measure. In order to screen out the best items that fit the predictive model, we adjusted the
249 significant value by using the Bonferroni correction (marked with $P_{Bonferroni}$). So that
250 predictive performance of network degree was evaluated for MSLT sleep latency by stepwise
251 linear models with leave-one-out cross-validation (LOOSWR). Network degrees were fit into
252 linear regression with adjustment of subject's sex, age, and constant. Using both forward and

253 backward iterations (entered a model), iterations with a significance < 0.05 were count and its
254 proportion was analyzed. Predicted MSLT sleep latency were compared using Pearson
255 correlation coefficients too. For all the statistical analysis, the level of significance was set at
256 $P < 0.05$. Majority of the computations were performed in the Python engine. All the
257 statistical process and analysis code are available at <https://github.com/Jiaji-Lab>.

258 **3. Results**

259 **3.1 Basic characteristics of people with narcolepsy**

260 The data of 30 participants with narcolepsy (Male: Female = 18: 12) were finally
261 collected, of which 56.67% (17/30) were type 1 with cataplexy and 43.33% (13/30) were type
262 2 without cataplexy. The mean age (\pm SD) of all people with narcolepsy was 29.5 ± 13.5
263 years. People with narcolepsy explicitly complained of EDS with a mean duration of $10.0 \pm$
264 7.0 years, with significantly higher ESS score than matched HCs (15.4 ± 5.2 vs. 2.8 ± 2.0 , $P <$
265 0.001). Moreover, 20.00% (6/30) of people with narcolepsy had sleep paralysis, 40.00%
266 (12/30) hypnagogic hallucinations, and 63.33% (19/30) RBD, respectively. In the present
267 study, all people with narcolepsy are treatment naïve and no other chronic medication has
268 been found. There were 76.67% (23/30) of people with narcolepsy had nSOREMP in
269 diagnostic PSG examination. It was also found that all the people with narcolepsy had more
270 than 2 SOREMPs in MSLT test with low MSLT sleep latency of 2.25 ± 1.39 min. Brain MRI
271 revealed no gross abnormalities in any participants with narcolepsy or HCs. Detail
272 demographic and narcoleptic characteristics were summarized in Table 1.

273 3.2 Topology features of structural network in people with narcolepsy

274 To study the alterations in brain structural network of people with narcolepsy, all the
275 structural connectivities of each participant were constructed. Non-paired *t*-test for each
276 structural connectivity was calculated between people with narcolepsy and matched HCs, and
277 all *t*-values were collected for global contrast matrix and converted into *t*-values distribution
278 (Fig. 1A). As *t*-values distribution shown, a wide range of structural connectivities were
279 found to endure a remarkable decrease without FDR correction in people with narcolepsy
280 compared with matched HCs, as well as a small fraction of enhanced connectivities (Fig. 1B
281 and Supplementary Figure 2). The most significant decreased structural connectivity were
282 right ventrolateral area 6 (A6vl_R) of MFG to right inferior frontal junction (IFJ_R) of MFG
283 ($t = -5.594$, $n = 30$), left caudal hippocampus (cHipp_L) to left caudal temporal thalamus
284 (cTtha_L) ($t = -5.481$, $n = 30$), and left rostral area 35/36 (A35/36r_L) of PhG to cHipp_L (t
285 $= -5.328$, $n = 30$).

286 Graph metrics of global structural network were calculated and a significant decrease in
287 the network degree in people with narcolepsy were observed compared to matched HCs
288 ($P_{\text{FDR}} < 0.001$) as well as global efficiency ($P_{\text{FDR}} < 0.001$, Fig. 1C). There was no significant
289 difference in clustering coefficient between narcolepsy and HC group (Fig. 1C). We further
290 divided all participants with narcolepsy into +cataplexy group (narcolepsy type 1, $n = 17$) and
291 -cataplexy group (narcolepsy type 2, $n = 13$). Although both network degree and global
292 efficiency showed a significant decline in +/-cataplexy participants compared with their
293 matched HCs (network degree: $P_{\text{FDR}} < 0.001$; global efficiency: $P_{\text{FDR}} < 0.001$; Fig. 1C), there
294 was no significant difference in the comparison between +cataplexy group and -cataplexy
295 group ($P_{\text{FDR}} > 0.05$; Fig. 1C). Moreover, no significant difference was found for other clinical
296 characteristics (sleep paralysis, hypnagogic hallucination and RBD; data not shown) among

297 people with narcolepsy. For regional metrics analysis, nodal degree of 33 ROIs and nodal
298 efficiency of 150 ROIs were found endured significant declines after FDR correction of all
299 ROIs ($P_{\text{FDR}} < 0.05$, Fig. 1D). Further detailed information could be found in the
300 Supplementary Table 2-3.

301 As for small but significant positive peak in t -values distribution of contrast matrix, we
302 tried network-based statistics to better identify the hyperenhanced subnetwork. The analysis
303 revealed a small subnetwork within 7 ROIs ($P_{\text{FDR}} < 0.001$), including both sides of caudal
304 area 23 (A23c_L and A23c_R) of CG, right ventral caudate (vCa_R), globus pallidus (GP_R)
305 and dorsal caudate (dCa_R) of BG, and left medial pre-frontal thalamus (mPFtha_L) and
306 rostral temporal thalamus (rTtha_L) of Tha (Fig. 1E). Graph metrics of this subnetwork were
307 not only found increased in the people with narcolepsy (network degree: $P_{\text{FDR}} < 0.001$;
308 global efficiency: $P_{\text{FDR}} < 0.001$, Fig. 1F), but also presented a similar significant increase
309 in +/-cataplexy participants compared with their matched HCs (network degree: $P_{\text{FDR}} <$
310 0.001 ; global efficiency: $P_{\text{FDR}} < 0.001$; Fig. 1F). Although no significant alteration could be
311 found in either +/-paralysis or +/-hallucination comparison, there was also a significant
312 increased in the people with narcolepsy with RBD vs. without RBD (network degree:
313 $P_{\text{FDR}} < 0.05$; global efficiency: $P_{\text{FDR}} < 0.05$; Fig. 1F). So that it was referred to as the
314 RBD-sensitive subnetwork.

315 **3.3 Linking structural topology to clinical characteristics of people with narcolepsy**

316 We analyzed the correlation between graph metrics and clinical characteristics within
317 people with narcolepsy. Although neither network degree nor global efficiency was
318 correlated with gender, age, ESS score, or REM latency in PSG, it turned out that both
319 network degree and global efficiency were positively correlated with MSLT sleep latency
320 (network degree: $r = 0.59$, $P < 0.001$; global efficiency: $r = 0.55$, $P = 0.002$; Fig.2A).

321 Similarly, they were also positively correlated with sleep latency in PSG (network degree: $r =$
322 0.54 , $P = 0.002$; global efficiency: $r = 0.51$, $P = 0.004$; Fig.2A). Moreover, they endured a
323 significant negative correlation with WASO (network degree: $r = -0.45$, $P = 0.013$; global
324 efficiency: $r = -0.45$, $P = 0.012$) and AWN (network degree: $r = -0.38$, $P = 0.039$; Fig.2B).
325 As for sleep macrostructure, global efficiency but not network degree was negatively
326 correlated with the N1 sleep time ($r = -0.36$, $P = 0.047$) and percentage ($r = 0.37$,
327 $P = 0.043$; Fig.2C). Not only the network degree was positively correlated with the N2
328 sleep time ($r = 0.44$, $P = 0.015$) and percentage ($r = 0.38$, $P = 0.037$), but also the
329 network global efficiency was significantly correlated (N2 sleep time: $r = 0.51$, $P = 0.004$;
330 N2 sleep percentage: $r = 0.46$, $P = 0.009$; Fig.2C). No metrics was found correlated with
331 N3 or REM sleep or other clinical characteristics. Finally, we also studied the graph metrics
332 of RBD-sensitive subnetwork, and it only had significant correlation with RBD symptoms
333 (subnetwork degree: spearman $r = 0.36$, $P = 0.0482$; subnetwork global efficiency:
334 spearman $r = 0.41$, $P = 0.024$). No other significant correlation was found for RBD-
335 sensitive subnetwork within people with narcolepsy.

336 We adjusted the significant value of clinical correlation by using the Bonferroni
337 correction. As remarkable correlation with MSLT sleep latency ($P_{\text{Bonferroni}} < 0.05$), network
338 degree was also applied in LOOSWR for MSLT Sleep latency prediction with adjustment of
339 gender and age. It was found that network degree could be used as reliable biomarkers for
340 MSLT sleep latency prediction ($r = 0.71$; iterative repetition = 100%, $P_{\text{FDR}} < 0.05$).

341 **3.4 Linking structural narcolepsy topology to glutamatergic neuropathophysiology**

342 We performed a PLS-based gene analysis to identify genes that were highly correlated
343 with alterations of structural network in people with narcolepsy. Gene expression networks of

344 both hemispheres of the healthy adult brain were constructed using the AHBA³⁷. The
345 primary PLS features of narcolepsy genes accounted for 21.19% of the total variance with the
346 $P < 0.001$ based on 5,000 permutations. These rank-list of narcolepsy-featured genes were
347 annotated, and the Panther pathway analysis identified that these featured genes were
348 functionally enriched in Metabotropic glutamate receptor (mGluR) group I pathway
349 (P00041, $P_{FDR} < \square 0.001$), Ionotropic glutamate receptor (iGluR) pathway (P00037, P_{FDR}
350 $< \square 0.001$) and Interferon-gamma (IFN γ) signaling pathway (P00035, $P_{FDR} < \square 0.001$; Fig.
351 3A). We then further investigated their GO characteristics. A post-processing step of affinity
352 propagation revealed that the representative biological processes of the narcolepsy-featured
353 genes were synaptic vesicle cycle (GO0099504), regulation of synapse structure or activity
354 (GO:0050803), glutamate receptor signaling pathway (GO0007215) and regulation of
355 membrane potential (GO0042391) (all $P_{FDR} < \square 0.001$; Fig. 3B). Majority of cellular
356 components focused on synaptic membrane (GO: 0097060) and glutamatergic synapse
357 (GO:0098978) (all $P_{FDR} < \square 0.001$; Fig. 3B). All the top gene functional properties were
358 provided in Supplementary Tables 4-6.

359 As glutamatergic neuropathophysiology had the highest significance in functional
360 analysis, we tried further verification by glutamatergic PET/SPECT data from unrelated
361 healthy subjects. With 5,000 SA-preserving surrogate maps as null models, there were
362 significant correlations between the global network degree and mGluR5 ($r = -0.37, -0.38$ and
363 -0.35 respectively for Rosa-Neto, Dubois and Smart data, all $P < \square 0.001$; Fig. 3C) and
364 NMDA ($r = -0.34$ for Galovic data, $P < \square 0.001$; Fig. 3D).

365 **4. Discussion**

366 In our present study, we explored the abnormal alteration in the overall structural
367 network in people with narcolepsy, revealing a wide and significant wiring decline. It not
368 only suggested a dramatic decrease in global efficiency of structural connectivity, but also
369 showed a significant clinical correlation with shorter sleep latency, more frequently nocturnal
370 awakening, and disrupted sleep macrostructure. It also showed that this structural alteration
371 was closely linked to functional signature of glutamatergic neuropathophysiology, while
372 additional PET/SPECT data verified that this structural alteration was significantly correlated
373 with mGluR5 and NMDA. All these suggest that we need to pay more attention to the
374 neuroplasticity features underlying the brain connectome adaptation in narcolepsy.

375 The human brain is a complex computational system which is widely connected by
376 network of “highways” the information flow along. With the improvement of non-invasive
377 imaging systems, much efforts toward investigating brain connectome focuses on the
378 application of graph theoretical analysis, which facilitates explorations of the information
379 propagation, integration, and segregation that characterize the topology of the network³⁸. It is
380 widely reported in various neurological diseases, such as dementia, multiple sclerosis and
381 stroke, that a bunch of architectural features are found sensitive to early disease diagnosis and
382 symptom assessment, including efficiency³⁹, modularity⁴⁰, network hubs⁴¹, and rich-club
383 organization⁴². In recent years, alterations in connectome have been found to be also
384 sensitive to sleep disorders. For example, people with insomnia present a hyperconnectivity
385 subnetwork related to right angular gyrus which contributes to increased reactivity and
386 vulnerability⁴³; obstructive sleep apnea makes people more prone to connectivity
387 dysfunction in the key nodes of the executive network and DMN⁴⁴. Most of studies on sleep
388 disorder have focused on functional abnormalities, while structural abnormalities are reported

389 infrequently. In our study, however, we found solid evidence that the structural networks in
390 people with narcolepsy were remarkably damaged, so that the overall topological
391 characteristics of the structural architecture were dramatically impaired. Although the
392 topological metrics of people with narcolepsy presented little difference between subtypes,
393 the descending structural properties of people with narcolepsy showed a close association
394 with various symptoms (MLST sleep latency, awakening at night PSG and sleep
395 macrostructure), suggesting an urge of studying the pathophysiological mechanism of the
396 white matter damage in people with narcolepsy.

397 In addition to further mining structural biomarkers for narcolepsy, we also need to pay
398 attention to the role that structural connectivity in shaping the brain activity dynamics of
399 people with narcolepsy. Tremendous efforts in the early theoretical simulations relating
400 structural and functional connectivity highlight that anatomical variability is one of the major
401 factors that promote individualized static brain activity ^{45,46}. And modelling functional
402 connectivity has not only use of brain structural connectivity data of a healthy brain but also
403 increasing need for that of brain disease ^{47,48}. In the study of narcolepsy, adolescent with
404 narcolepsy exhibit disrupted small-world network properties in functional activity as well as
405 regional alterations in the caudate nucleus and posterior cingulate gyrus ³. The abnormal
406 connectivities between the hypothalamus and brain regions involve in memory consolidation
407 during sleep, such as the hippocampus, may be linked to the loss of hypocretin neurons in the
408 dorsolateral hypothalamus ⁴⁹. Further understanding the spatial properties, temporal dynamics,
409 and spectral features of brain activity dynamics in narcolepsy asks for study deeper
410 characteristics of the structural connectivity itself as well as structure-function relationship
411 research.

412 One highlighted point during our connectome analysis is the anomalously enhanced
413 subnetwork involving the thalamus, striatum, and CG that was closely associated with RBD.

414 RBD is characterized by a loss of RWA together with prominent motor behavioral
415 manifestations associated with dreaming during REM sleep 50. Narcolepsy seems to be the
416 second most common cause of “secondary” RBD, accounting for about 10-15% of cases 51.
417 However, whether it is an intrinsic feature or associated feature is a still unclear
418 pathophysiology 52. Clinical studies have shown that narcolepsy RBD mainly affects
419 children or young patients under the age of 50, with no difference in gender distribution,
420 while idiopathic RBD or parkinsonism RBD is more common in middle-aged men 51. The
421 incidence of RBD in narcolepsy type 1 ranged from 7% to 63% in different cohorts 52, while
422 in some reports, the incidence of RBD in narcolepsy type 2 patients appeared to be much
423 lower than that in narcolepsy type 1 (37% vs. 15%) 53. It is worth emphasizing the incidence
424 of narcolepsy RBD can be easily overlooked, leading to an underestimation of the real
425 prevalence 52. Overall, studies based on clinical interviews reported an approximate
426 prevalence of 60-70%, which drops down to 2-50% in studies adopting video-PSG 52. And
427 although these less violent RBD in narcolepsy may be an early symptom in childhood and
428 preceded in severity and frequency with the aging process 54, there is currently no indication
429 that they would develop symptoms or signs of neurodegenerative disorders as idiopathic
430 RBD did 55. All these may suggest potential circuit mechanism differences between
431 narcolepsy RBD and idiopathic RBD. In our present analysis, we found that the RBD-
432 sensitive subnetwork in people with narcolepsy were mainly linked to CG, which was clearly
433 different from the brainstem destruction (especially in sublateralodorsal tegmental nucleus) in
434 idiopathic RBD 56,57. Therefore, it would be interesting to further characterize RBD-
435 sensitive subnetwork in people with idiopathic RBD.

436 Further imaging genetics indicated that a glutamatergic neuropathophysiology
437 mechanism may be underlying all above connectome remodeling in people with narcolepsy.
438 It is well known that the hypocretin system regulates sleep/wake control via complex

439 interactions with monoaminergic, cholinergic and GABA-ergic neuronal systems⁵⁸. The
440 highly selective and severe loss of the hypocretinergic neurons promoted excessive daytime
441 sleepiness, especially in the narcolepsy type 1⁵⁹. Various studies have shown that the activity
442 of hypocretin is closely related to glutamate: (1) During hypocretin releasing, it also attaches
443 to glutaminergic receptor and induces positive feedback of following hypocretin release^{60,61}.
444 (2) Hypocretinergic neurons release a lot of glutamate, which synergizes with the excitatory
445 effects of hypocretin^{62,63}. When glutamate receptors are blocked, hypocretin does not exert
446 its excitatory effect on motor neurons^{62,63}. (3) Hypocretinergic neurons also secrete neuronal
447 activity-regulated pentraxin (NARP), a protein that promotes clustering of glutamatergic
448 receptors at excitatory synapses and enhance postsynaptic responses to glutamate^{64,65}.
449 Whether this glutamatergic neuropathophysiology is also involved in the development of
450 narcolepsy subtype 2 has not been clearly reported. It's worthy of our further exploration of
451 their biological regulation within different narcolepsy subtypes.

452 One important limitation of this study is that most people with narcolepsy lacked
453 hypocretin data. In recent years, more and more studies emphasize the importance of
454 hypocretin in the pathogenesis of narcolepsy. In the text revision of ICSD-3 (ICSD-3-TR)
455 released in 2023 (<https://learn.aasm.org/Listing/a1341000002XmRvAAK>), it is
456 recommended that any potential person with narcolepsy should accept the hypocretin
457 radioimmunoassay for diagnose and classification. However, there has been a considerable
458 controversy over the standard of CSF hypocretin suitable for Chinese people with narcolepsy.
459 Professor Fang Han pointed out in 2013 that the Chinese people's CSF hypocretin was
460 relatively lower than westerners⁶⁶. In his reports, the level of 138.0 ng/L may be the optimal
461 cutoff for the diagnosis of people with narcolepsy type 1. Since that, his and other Chinese
462 teams have kept trying to find other reliable alternative biomarkers for narcolepsy, such as
463 DQB1*0602⁶⁷. To deal with this problem, Professor Shuqin Zhan of Xuanwu Hospital

464 initiated a multicenter study of clinical characterization and related biomarkers in narcolepsy
465 in China since 2021 (ID: ChiCTR2100052316; public site:
466 <https://www.chictr.org.cn/showproj.html?proj=126978>). We also join this project and hope it
467 will provide a solid answer to the long-standing debate on the hypocretin criteria for Chinese
468 people with narcolepsy. We will also conduct further structural study in the subsequent
469 research based on the new optimal cutoff for CSF hypocretin for Chinese.

470 Several other methodological considerations should also be contemplated when
471 interpreting the results of this study. Our findings are based on structural data determined
472 using diffusion tractography. The limitation of this method includes the uncertainty of
473 crossing fibers. There would be an improvement if high-angular resolution diffusion-
474 weighted imaging or spherical deconvolution post-processing techniques are used to provide
475 the best possible estimate of the underlying structural connectivity⁶⁸. Using transcriptome
476 and PET/SPECT data from healthy human brains could be limited if the narcolepsy gene
477 expression patterns are different from those of healthy brains.

478

479

480

481

482 **5. Acknowledgments**

483 This work has been supported by the Key R&D Program of Shaanxi Province (Grant
484 No. 2022ZDLSF03-07).

485 **6. Conflict of Interest**

486 The authors declare that they have no competing interests.

487 **7. Disclosure Statement**

488 Financial Disclosure: none. Non-financial Disclosure: none.

489 **8. References**

- 490 1. Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy - clinical spectrum,
491 aetiopathophysiology, diagnosis and treatment. *Nature reviews Neurology*. 2019; 15 (9): 519-
492 539.
- 493 2. Trotti LM, Saini P, Crosson B, Meltzer CC, Rye DB, Nye JA. Regional brain
494 metabolism differs between narcolepsy type 1 and idiopathic hypersomnia. *Sleep*. 2021; 44
495 (8).
- 496 3. Fulong X, Spruyt K, Chao L, Dianjiang Z, Jun Z, Fang H. Resting-state brain network
497 topological properties and the correlation with neuropsychological assessment in adolescent
498 narcolepsy. *Sleep*. 2020; 43 (8).
- 499 4. Poryazova R, Schnepf B, Werth E, et al. Evidence for metabolic hypothalamo-
500 amygdala dysfunction in narcolepsy. *Sleep*. 2009; 32 (5): 607-613.

- 501 5. van den Heuvel MP, Sporns O. A cross-disorder connectome landscape of brain
502 dysconnectivity. *Nature reviews Neuroscience*. 2019; 20 (7): 435-446.
- 503 6. van den Heuvel MP, Bullmore ET, Sporns O. Comparative Connectomics. *Trends in*
504 *cognitive sciences*. 2016; 20 (5): 345-361.
- 505 7. Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic
506 functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease.
507 *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2009; 29
508 (6): 1860-1873.
- 509 8. Verstraete E, Veldink JH, van den Berg LH, van den Heuvel MP. Structural brain
510 network imaging shows expanding disconnection of the motor system in amyotrophic lateral
511 sclerosis. *Human brain mapping*. 2014; 35 (4): 1351-1361.
- 512 9. Pedersen M, Omidvarnia A, Curwood EK, Walz JM, Rayner G, Jackson GD. The
513 dynamics of functional connectivity in neocortical focal epilepsy. *NeuroImage Clinical*.
514 2017; 15: 209-214.
- 515 10. Uddin LQ, Supekar K, Menon V. Reconceptualizing functional brain connectivity in
516 autism from a developmental perspective. *Frontiers in human neuroscience*. 2013; 7: 458.
- 517 11. Gool JK, Fronczek R, Leemans A, Kies DA, Lammers GJ, Van der Werf YD.
518 Widespread white matter connectivity abnormalities in narcolepsy type 1: A diffusion tensor
519 imaging study. *NeuroImage Clinical*. 2019; 24: 101963.
- 520 12. Tezer FI, Erdal A, Gumusyayla S, Has AC, Gocmen R, Oguz KK. Differences in
521 diffusion tensor imaging changes between narcolepsy with and without cataplexy. *Sleep*
522 *medicine*. 2018; 52: 128-133.
- 523 13. Park YK, Kwon OH, Joo EY, et al. White matter alterations in narcolepsy patients
524 with cataplexy: tract-based spatial statistics. *Journal of sleep research*. 2016; 25 (2): 181-189.

- 525 14. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory.
526 *Neuropsychologia*. 1971; 9 (1): 97-113.
- 527 15. Sateia MJ. International classification of sleep disorders-third edition: highlights and
528 modifications. *Chest*. 2014; 146 (5): 1387-1394.
- 529 16. Berry RB, Brooks R, Gamaldo C, et al. AASM Scoring Manual Updates for 2017
530 (Version 2.4). *Journal of clinical sleep medicine : JCSM : official publication of the*
531 *American Academy of Sleep Medicine*. 2017; 13 (5): 665-666.
- 532 17. Lin J, Kang X, Xiong Y, et al. Convergent structural network and gene signatures for
533 MRgFUS thalamotomy in patients with Parkinson's disease. *NeuroImage*. 2021; 243: 118550.
- 534 18. Yu C, Zhou Y, Liu Y, et al. Functional segregation of the human cingulate cortex is
535 confirmed by functional connectivity based neuroanatomical parcellation. *NeuroImage*. 2011;
536 54 (4): 2571-2581.
- 537 19. Zalesky A, Fornito A, Bullmore ETJN. Network-based statistic: identifying
538 differences in brain networks. 2010; 53 (4): 1197-1207.
- 539 20. Xu K, Liu Y, Zhan Y, Ren J, Jiang T. BRANT: a versatile and extendable resting-
540 state fMRI toolkit. *Frontiers in neuroinformatics*. 2018; 12: 52.
- 541 21. Rubinov M, Sporns OJN. Complex network measures of brain connectivity: uses and
542 interpretations. 2010; 52 (3): 1059-1069.
- 543 22. Barthelemy MJTEpjB. Betweenness centrality in large complex networks. 2004; 38
544 (2): 163-168.
- 545 23. Smith P, Hutchison D, Sterbenz JP, et al. Network resilience: a systematic approach.
546 2011; 49 (7): 88-97.
- 547 24. Phillips C, Swiler LP. A graph-based system for network-vulnerability analysis. In:
548 proceedings from the Proceedings of the 1998 workshop on New security paradigms; 1998.

- 549 25. Najjar W, Gaudiot J-LJIToC. Network resilience: A measure of network fault
550 tolerance. 1990; 39 (2): 174-181.
- 551 26. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically
552 comprehensive atlas of the adult human brain transcriptome. Nature. 2012; 489 (7416): 391-
553 399.
- 554 27. *abagen: A toolbox for the Allen Brain Atlas genetics data* [computer program]. 2020.
- 555 28. Arnatkeviciute A, Fulcher BD, Fornito A. A practical guide to linking brain-wide
556 gene expression and neuroimaging data. Neuroimage. 2019; 189: 353-367.
- 557 29. Seidlitz J, Vasa F, Shinn M, et al. Morphometric Similarity Networks Detect
558 Microscale Cortical Organization and Predict Inter-Individual Cognitive Variation. Neuron.
559 2018; 97 (1): 231-247 e237.
- 560 30. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis
561 toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019; 47 (W1): W199-W205.
- 562 31. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a
563 knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad
564 Sci U S A. 2005; 102 (43): 15545-15550.
- 565 32. Hansen JY, Shafiei G, Markello RD, et al. Mapping neurotransmitter systems to the
566 structural and functional organization of the human neocortex. Nature neuroscience. 2022; 25
567 (11): 1569-1581.
- 568 33. DuBois JM, Rousset OG, Rowley J, et al. Characterization of age/sex and the regional
569 distribution of mGluR5 availability in the healthy human brain measured by high-resolution
570 [(11)C]ABP688 PET. European journal of nuclear medicine and molecular imaging. 2016; 43
571 (1): 152-162.

- 572 34. Smart K, Cox SML, Scala SG, et al. Sex differences in [(11)C]ABP688 binding: a
573 positron emission tomography study of mGlu5 receptors. *European journal of nuclear*
574 *medicine and molecular imaging*. 2019; 46 (5): 1179-1183.
- 575 35. Galovic M, Erlandsson K, Fryer TD, et al. Validation of a combined image derived
576 input function and venous sampling approach for the quantification of [(18)F]GE-179 PET
577 binding in the brain. *NeuroImage*. 2021; 237: 118194.
- 578 36. Burt JB, Helmer M, Shinn M, Anticevic A, Murray JD. Generative modeling of brain
579 maps with spatial autocorrelation. *Neuroimage*. 2020; 220: 117038.
- 580 37. Hawrylycz M, Miller JA, Menon V, et al. Canonical genetic signatures of the adult
581 human brain. 2015; 18 (12): 1832.
- 582 38. Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and
583 interpretations. *NeuroImage*. 2010; 52 (3): 1059-1069.
- 584 39. Latora V, Marchiori M. Efficient behavior of small-world networks. *Physical review*
585 *letters*. 2001; 87 (19): 198701.
- 586 40. Sporns O, Betzel RF. Modular Brain Networks. *Annual review of psychology*. 2016;
587 67: 613-640.
- 588 41. van den Heuvel MP, Sporns O. Network hubs in the human brain. *Trends in cognitive*
589 *sciences*. 2013; 17 (12): 683-696.
- 590 42. van den Heuvel MP, Sporns O. Rich-club organization of the human connectome. *The*
591 *Journal of neuroscience : the official journal of the Society for Neuroscience*. 2011; 31 (44):
592 15775-15786.
- 593 43. Wei Y, Bresser T, Wassing R, Stoffers D, Van Someren EJW, Foster-Dingley JC.
594 Brain structural connectivity network alterations in insomnia disorder reveal a central role of
595 the right angular gyrus. *NeuroImage Clinical*. 2019; 24: 102019.

- 596 44. Canessa N, Castronovo V, Cappa SF, et al. Sleep apnea: Altered brain connectivity
597 underlying a working-memory challenge. *NeuroImage Clinical*. 2018; 19: 56-65.
- 598 45. Ghosh A, Rho Y, McIntosh AR, Kötter R, Jirsa VK. Noise during rest enables the
599 exploration of the brain's dynamic repertoire. *PLoS computational biology*. 2008; 4 (10):
600 e1000196.
- 601 46. Honey CJ, Sporns O, Cammoun L, et al. Predicting human resting-state functional
602 connectivity from structural connectivity. *Proceedings of the National Academy of Sciences*
603 of the United States of America. 2009; 106 (6): 2035-2040.
- 604 47. Zhang F, Daducci A, He Y, et al. Quantitative mapping of the brain's structural
605 connectivity using diffusion MRI tractography: A review. *NeuroImage*. 2022; 249: 118870.
- 606 48. Hlinka J, Coombes S. Using computational models to relate structural and functional
607 brain connectivity. *The European journal of neuroscience*. 2012; 36 (2): 2137-2145.
- 608 49. Ballotta D, Talami F, Pizza F, et al. Hypothalamus and amygdala functional
609 connectivity at rest in narcolepsy type 1. *NeuroImage Clinical*. 2021; 31: 102748.
- 610 50. Sateia MJ. *International Classification of Sleep Disorders-Third Edition*. Chest. 2014;
611 146 (5): 1387-1394.
- 612 51. Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder.
613 *Nature reviews Disease primers*. 2018; 4 (1): 19.
- 614 52. Antelmi E, Pizza F, Franceschini C, Ferri R, Plazzi G. REM sleep behavior disorder
615 in narcolepsy: A secondary form or an intrinsic feature? *Sleep medicine reviews*. 2020; 50:
616 101254.
- 617 53. Nevsimalova S, Pisko J, Buskova J, et al. Narcolepsy: clinical differences and
618 association with other sleep disorders in different age groups. *Journal of neurology*. 2013;
619 260 (3): 767-775.

- 620 54. Nevsimalova S, Prihodova I, Kemlink D, Lin L, Mignot E. REM behavior disorder
621 (RBD) can be one of the first symptoms of childhood narcolepsy. *Sleep medicine*. 2007; 8 (7-
622 8): 784-786.
- 623 55. Knudsen S, Gammeltoft S, Jennum PJ. Rapid eye movement sleep behaviour disorder
624 in patients with narcolepsy is associated with hypocretin-1 deficiency. *Brain : a journal of*
625 *neurology*. 2010; 133 (Pt 2): 568-579.
- 626 56. Shen Y, Yu WB, Shen B, et al. Propagated α -synucleinopathy recapitulates REM
627 sleep behaviour disorder followed by parkinsonian phenotypes in mice. *Brain : a journal of*
628 *neurology*. 2020; 143 (11): 3374-3392.
- 629 57. Valencia Garcia S, Libourel PA, Lazarus M, Grassi D, Luppi PH, Fort P. Genetic
630 inactivation of glutamate neurons in the rat sublateralodorsal tegmental nucleus recapitulates
631 REM sleep behaviour disorder. *Brain : a journal of neurology*. 2017; 140 (2): 414-428.
- 632 58. Nepovimova E, Janockova J, Misik J, et al. Orexin supplementation in narcolepsy
633 treatment: A review. *Medicinal research reviews*. 2019; 39 (3): 961-975.
- 634 59. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin)
635 deficiency in human narcolepsy. *Lancet (London, England)*. 2000; 355 (9197): 39-40.
- 636 60. Schöne C, Burdakov D. Glutamate and GABA as rapid effectors of hypothalamic
637 "peptidergic" neurons. *Frontiers in behavioral neuroscience*. 2012; 6: 81.
- 638 61. Schöne C, Apergis-Schoute J, Sakurai T, Adamantidis A, Burdakov D. Coreleased
639 orexin and glutamate evoke nonredundant spike outputs and computations in histamine
640 neurons. *Cell reports*. 2014; 7 (3): 697-704.
- 641 62. Plaza-Zabala A, Li X, Milovanovic M, et al. An investigation of interactions between
642 hypocretin/orexin signaling and glutamate receptor surface expression in the rat nucleus
643 accumbens under basal conditions and after cocaine exposure. *Neuroscience Letters*. 2013;
644 557: 101-106.

- 645 63. Acuna-Goycolea C, Li Y, Van Den Pol AN. Group III metabotropic glutamate
646 receptors maintain tonic inhibition of excitatory synaptic input to hypocretin/orexin neurons.
647 The Journal of neuroscience : the official journal of the Society for Neuroscience. 2004; 24
648 (12): 3013-3022.
- 649 64. Chang MC, Park JM, Pelkey KA, et al. Narx regulates homeostatic scaling of
650 excitatory synapses on parvalbumin-expressing interneurons. Nature neuroscience. 2010; 13
651 (9): 1090-1097.
- 652 65. Reti IM, Reddy R, Worley PF, Baraban JM. Selective expression of Narx, a secreted
653 neuronal pentraxin, in orexin neurons. Journal of neurochemistry. 2002; 82 (6): 1561-1565.
- 654 66. Dong XS, Li YQ, Li J, et al. [Value of cerebral spinal fluid measurement of
655 hypocretin-1 in the diagnosis of Chinese patients with narcolepsy]. Zhonghua yi xue za zhi.
656 2013; 93 (26): 2038-2042.
- 657 67. Chang Y, Dong XS, Li J, et al. [Predictive value of typical cataplexy+ DQB1*0602
658 positive to hypocretin-1 reduction in cerebrospinal fluid in patients with narcolepsy].
659 Zhonghua yi xue za zhi. 2018; 98 (40): 3253-3257.
- 660 68. Alakurtti K, Johansson JJ, Joutsa J, et al. Long-term test–retest reliability of striatal
661 and extrastriatal dopamine D2/3 receptor binding: study with [11C] raclopride and high-
662 resolution PET. 2015; 35 (7): 1199-1205.
- 663

664 **Figure Legend**

665 **Figure 1 Topology features of structural network in people with narcolepsy** (A) An
666 overview for building the contrast matrix. (B) The narcolepsy featured t -values distribution.
667 (C) Group comparison of topological features in the global structural network of people with
668 narcolepsy and matched HCs as well as subgroups. (D) The t -value in the comparison of
669 regional topological features (nodal degree and nodal efficiency), where the dashed line
670 represented the t -value threshold after FDR correction. (E) Network-based statistics revealed
671 a subnetwork of hyperenhanced connectivity strength in people with narcolepsy. (F) Group
672 comparison of topological features in the RBD-sensitive subnetwork of people with
673 narcolepsy and matched HCs as well as subgroups. (^{ns} $P_{FDR} > 0.05$, * $P_{FDR} < 0.05$, *** $P_{FDR} <$
674 0.001)

675 **Figure 2 Linking structural topology to clinical characteristics of people with**
676 **narcolepsy** Correlation results between metrics of global structural network of people with
677 narcolepsy and MSLT sleep latency (A), sleep latency at PSG (A), wake time after sleep
678 onset (B), awakening number per hour (B), N1 sleep time and percentage (C) and N2 sleep
679 time and percentage (D).

680 **Figure 3 Linking structural narcolepsy topology to glutamatergic neuropathophysiology**
681 (A) Significant results of Panther pathway terms in the functional enrichment analysis
682 performed by WebGestalt. (B) Bar graph of GO enrichment analysis based on affinity
683 propagation for narcolepsy-featured genes. (C) Further verification by glutamatergic
684 PET/SPECT data.

685

686

Table 1 Characteristics of the study population

	Patients (n = 30)	Matched HCs (n = 30)	<i>P</i> value
Basic information			
Male: Female	18:12	18:12	<i>P</i> > 0.05
Age (years, mean, SD)	29.5 (13.5)	29 (12.8)	<i>P</i> > 0.05
Narcolepsy features			
NT1/NT2 (n/n)	17/13	-	-
EDS (n/total)	30/30	0/30	<i>P</i> < 0.001
EDS duration (years, mean, SD)	10.0 (7.0)	-	-
ESS score (mean, SD)	15.4 (5.2)	2.8 (2.0)	<i>P</i> < 0.001
Cataplexy (n/total)	17/30	0/30	<i>P</i> < 0.001
Sleep paralysis (n/total)	6/30	0/30	<i>P</i> < 0.001
Hypnagogic hallucinations (n/total)	12/30	0/30	<i>P</i> < 0.001
RBD (n/total)	19/30	0/30	<i>P</i> < 0.001
RBD in NT1 (n/n)	12/17	-	-
RBD in NT2 (n/n)	7/13	-	-
Night polysomnography and MSLT			
TST (minutes, mean, SD)	411.7 (53.4)	-	-
Sleep efficiency (minutes, mean, SD)	85.6 (10.6)	-	-
Sleep latency (minutes, mean, SD)	9.0 (8.7)	-	-
REM latency (minutes, mean, SD)	88.9 (77.8)	-	-
nSOREMP (n/total)	23/30	-	-
N1% (mean, SD)	29.3 (10.3)	-	-
N2% (mean, SD)	39.5 (12.6)	-	-
N3% (mean, SD)	13.8 (6.4)	-	-
REM times (mean, SD)	4.6 (1.3)	-	-
REM% (mean, SD)	17.5 (6.2)	-	-
Wake time after sleep onset (WASO) (mean, SD)	26.5 (24)	-	-
Awakening number (AWN) per hour (mean, SD)	4.0 (3.4)	-	-
Arousal index (AI) (mean, SD)	3.8 (5.7)	-	-
Apnea-hypopnea index (AHI) (mean, SD)	2.6 (2.3)	-	-
Limb movement (LM) index (mean, SD)	22.1 (18.6)	-	-
Periodic leg movements (PLM) index (mean, SD)	9.1 (16.9)	-	-
Mean sleep latency in MLST (minutes, mean, SD)	2.25 (1.39)	-	-
SOREMPs in MSLT (mean, SD)	4.31 (0.99)	-	-

Note: HC: health control; NT1: narcolepsy type 1; NT2: narcolepsy type 2; EDS: excessive daytime sleepiness; RBD: rapid eye movement (REM) sleep behavior disorder; ESS: Epworth Sleepiness Scale; MSLT: multiple sleep latency test; TST: total sleep time; nSOREMP = nocturnal SOREMP in PSG; SOREMP = the sleep-onset REM period.

688
689
690

691

692





